VK2735
vs Retatrutide.
Compare VK2735 and retatrutide by dual versus triple agonism, oral and injectable routes, trial duration, Phase 3 status, results, and approval limits.
What is the difference?
VK2735 and retatrutide are separate investigational peptide programs with no randomized head-to-head trial. VK2735 activates GLP-1 and GIP receptors and is being developed as both a weekly injection and daily tablet. Retatrutide activates GIP, GLP-1, and glucagon receptors as a weekly injection. VK2735 has 13-week Phase 2 results and fully enrolled injectable Phase 3 trials without outcomes. Retatrutide has reported 80-week Phase 3 obesity results. Neither is FDA approved, and the available evidence cannot show that one is faster, stronger, safer, or better for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
VK2735
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection and once-daily oral tablet
- Registry
- 5 matched NCT records
- Sponsor
- Viking Therapeutics
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
VK2735 vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between VK2735 and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
VK2735
GIP and GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection and once-daily oral tablet
- Stage
- Subcutaneous Phase 3 active; oral Phase 3 planned
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 0
- Results posted
- 0
- Recruiting site observations
- 0
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
VK2735
GIP and GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection and once-daily oral tablet
- Stage
- Subcutaneous Phase 3 active; oral Phase 3 planned
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06068946 · NCT06828055 · NCT07104500 · NCT07104383
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
This comparison combines three distinct questions: whether VK2735 could offer an oral path, whether retatrutide's third receptor creates greater efficacy, and whether a short early result predicts a long-term winner. The evidence can compare formulation, receptor design, development stage, population, and adverse-event context. It cannot compare efficacy directly because the cited percentages come from separate trials with very different durations, dose escalation, analysis methods, and maturity.
| Field | VK2735 | Retatrutide | How to interpret it |
|---|---|---|---|
| Receptor design | GLP-1 and GIP receptor dual agonist | GIP, GLP-1, and glucagon receptor triple agonist | Retatrutide adds glucagon activity, but receptor count does not by itself predict comparative efficacy, tolerability, or benefit-risk. |
| Formulations studied | Once-weekly injection and once-daily oral tablet | Once-weekly subcutaneous injection | VK2735's two-formulation strategy is distinctive, but neither formulation has an approved commercial label or dosing schedule. |
| Evidence anchor | 14.7% injectable and 12.2% oral mean change at 13 weeks in separate Phase 2 trials | 28.3% mean change at 80 weeks in TRIUMPH-1 under an efficacy estimand | Different phases, durations, formulations, dose plans, and analyses make the headline percentages unsuitable for a speed or strength ranking. |
| Phase 3 status | Injectable VANQUISH trials fully enrolled with no posted outcomes | TRIUMPH program active and reporting Phase 3 outcomes | Enrollment and reported topline results are different milestones, and neither one is FDA marketing approval. |
| Current access status | Investigational and not FDA approved | Investigational and not FDA approved | Neither development name identifies an approved pharmacy product, retail price, legitimate online vial, or prescribing route. |
Why the headline numbers do not name a winner.
The 14.7% VK2735 result came from a 13-week Phase 2 trial of weekly injection, while the 12.2% oral result came from a separate 13-week tablet study. Retatrutide's 28.3% result came from the 12 mg arm of an 80-week Phase 3 trial under an efficacy estimand. Dividing either percentage by weeks or ranking the endpoints ignores dose escalation, plateau timing, discontinuation, population, placebo response, missing data, and the fact that participants were never randomized between VK2735 and retatrutide.
Keep the comparison honest.
- 01
Never convert a 13-week percentage and an 80-week percentage into a per-week efficacy ranking because weight trajectories and dose escalation are not linear.
- 02
Keep oral VK2735, injectable VK2735, and retatrutide attached to their separate trial records, populations, doses, analyses, and adverse-event data.
- 03
Treat Phase 3 enrollment and Phase 3 topline reporting as development milestones, not approval, commercial availability, or product authentication.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →